Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CVS HEALTH CorpCVS · Entity 2884 | Vice President | April 03, 2006 | April 05, 2006 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CVS HEALTH Corp
Report date April 03, 2006 · Filed April 05, 2006
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock (Restricted)SEC Table I · non-derivative | Direct | 30,161 |
Reported balance
After 2006-04-03 transaction · row 1
1 source rowRow 1 · 2006-04-03 · Grant · Acquired 4,161 · Balance 30,161 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.04 · Expires 2013-04-03 | Direct | 46,106 |
Reported balance
After 2006-04-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2006-04-03 · Grant · Acquired 46,106 · Balance 46,106 F1: Option becomes exercisable in three equal annual installments, commencing 4/3/07 |
Filing footnotes · ownership attribution and instrument terms
F1: Option becomes exercisable in three equal annual installments, commencing 4/3/07
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PharMerica CORP
Report date November 07, 2017 · Filed December 11, 2017
Section 16 reporting ended · disclosed 2017-12-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 444,001 |
Reported balance
After 2017-11-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-11-03 · Gift · Disposed 51,282 · Balance 444,001 F1: On November 3, 2017, the reporting person irrevocably transferred 51,282 shares to the Weishar Family Foundation. F2: The reported securities do not include 519,589 shares transferred on November 3, 2017 to the Greg S. Weishar Delaware Trust, for which securities the reporting person disclaims beneficial ownership except to the extent of his pecuniary interest therein. |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-12-07 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2017-12-07 · Disposition to issuer · Disposed 440,001 · Balance 0 F3: Pursuant to the terms of the Agreement and Plan of Merger, dated as of August 1, 2017 (the "Merger Agreement"), by and among PharMerica Corporation (the "Company"), Phoenix Parent Holdings Inc., a Delaware corporation ("Parent"), and Phoenix Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent, at the effective time ("Effective Time") of the merger, Merger Sub will merge with and into the Company, with the Company as the surviving entity and a wholly owned subsidiary of Parent. F4: Pursuant to the terms of the Merger Agreement, as of the Effective Time (i) a portion of the Company's common stock, par value $0.01 per share ("Company Common Stock") owned by the reporting person was converted into shares of Parent common stock, par value $0.01 per share, (ii)the remaining shares of Company Common Stock owned by the reporting person were converted into the right to receive $29.25 in cash without interest (the "Merger Consideration") and (iii) each outstanding restricted stock unit granted by the Company was converted automatically into a right to receive an amount in cash without interest equal to the product of (x) the number of shares of Company Common Stock subject to such unit, such number of shares based on target performance in the case of performance stock units, multiplied by (y) the Merger Consideration. |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectBy Trust | 0 |
Reported balance
After 2017-12-07 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2017-12-07 · Sale · Disposed 519,589 · Balance 0 F3: Pursuant to the terms of the Agreement and Plan of Merger, dated as of August 1, 2017 (the "Merger Agreement"), by and among PharMerica Corporation (the "Company"), Phoenix Parent Holdings Inc., a Delaware corporation ("Parent"), and Phoenix Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent, at the effective time ("Effective Time") of the merger, Merger Sub will merge with and into the Company, with the Company as the surviving entity and a wholly owned subsidiary of Parent. F4: Pursuant to the terms of the Merger Agreement, as of the Effective Time (i) a portion of the Company's common stock, par value $0.01 per share ("Company Common Stock") owned by the reporting person was converted into shares of Parent common stock, par value $0.01 per share, (ii)the remaining shares of Company Common Stock owned by the reporting person were converted into the right to receive $29.25 in cash without interest (the "Merger Consideration") and (iii) each outstanding restricted stock unit granted by the Company was converted automatically into a right to receive an amount in cash without interest equal to the product of (x) the number of shares of Company Common Stock subject to such unit, such number of shares based on target performance in the case of performance stock units, multiplied by (y) the Merger Consideration. |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectBy Son | 0 |
Reported balance
After 2017-12-07 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2017-12-07 · Sale · Disposed 1,500 · Balance 0 F3: Pursuant to the terms of the Agreement and Plan of Merger, dated as of August 1, 2017 (the "Merger Agreement"), by and among PharMerica Corporation (the "Company"), Phoenix Parent Holdings Inc., a Delaware corporation ("Parent"), and Phoenix Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent, at the effective time ("Effective Time") of the merger, Merger Sub will merge with and into the Company, with the Company as the surviving entity and a wholly owned subsidiary of Parent. F4: Pursuant to the terms of the Merger Agreement, as of the Effective Time (i) a portion of the Company's common stock, par value $0.01 per share ("Company Common Stock") owned by the reporting person was converted into shares of Parent common stock, par value $0.01 per share, (ii)the remaining shares of Company Common Stock owned by the reporting person were converted into the right to receive $29.25 in cash without interest (the "Merger Consideration") and (iii) each outstanding restricted stock unit granted by the Company was converted automatically into a right to receive an amount in cash without interest equal to the product of (x) the number of shares of Company Common Stock subject to such unit, such number of shares based on target performance in the case of performance stock units, multiplied by (y) the Merger Consideration. |
| Performance share unitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 146,521 |
Reported balance
After 2017-12-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-12-07 · Grant · Acquired 146,521 · Balance 146,521 F4: Pursuant to the terms of the Merger Agreement, as of the Effective Time (i) a portion of the Company's common stock, par value $0.01 per share ("Company Common Stock") owned by the reporting person was converted into shares of Parent common stock, par value $0.01 per share, (ii)the remaining shares of Company Common Stock owned by the reporting person were converted into the right to receive $29.25 in cash without interest (the "Merger Consideration") and (iii) each outstanding restricted stock unit granted by the Company was converted automatically into a right to receive an amount in cash without interest equal to the product of (x) the number of shares of Company Common Stock subject to such unit, such number of shares based on target performance in the case of performance stock units, multiplied by (y) the Merger Consideration. |
| Performance share unitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2017-12-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-12-07 · Disposition to issuer · Disposed 146,521 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, as of the Effective Time (i) a portion of the Company's common stock, par value $0.01 per share ("Company Common Stock") owned by the reporting person was converted into shares of Parent common stock, par value $0.01 per share, (ii)the remaining shares of Company Common Stock owned by the reporting person were converted into the right to receive $29.25 in cash without interest (the "Merger Consideration") and (iii) each outstanding restricted stock unit granted by the Company was converted automatically into a right to receive an amount in cash without interest equal to the product of (x) the number of shares of Company Common Stock subject to such unit, such number of shares based on target performance in the case of performance stock units, multiplied by (y) the Merger Consideration. |
| Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.84 · Expires 2018-03-25 | Direct | 0 |
Reported balance
After 2017-12-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-12-07 · Disposition to issuer · Disposed 182,801 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding employee option, whether vested or unvested ("Company Stock Option") became fully vested and was converted automatically into the right to receive an amount in cash without interest equal to the product of (x) the number of shares of Company Common Stock subject to such option, multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price per share of such Company Stock Option. F5: The options vested in the following amounts on the following dates: 45,700 options on 03/25/2012, 45,700 options on 03/25/2013, 45,700 options on 03/25/2014 and 45,701 options on 03/25/2015. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 3, 2017, the reporting person irrevocably transferred 51,282 shares to the Weishar Family Foundation.
F2: The reported securities do not include 519,589 shares transferred on November 3, 2017 to the Greg S. Weishar Delaware Trust, for which securities the reporting person disclaims beneficial ownership except to the extent of his pecuniary interest therein.
F3: Pursuant to the terms of the Agreement and Plan of Merger, dated as of August 1, 2017 (the "Merger Agreement"), by and among PharMerica Corporation (the "Company"), Phoenix Parent Holdings Inc., a Delaware corporation ("Parent"), and Phoenix Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent, at the effective time ("Effective Time") of the merger, Merger Sub will merge with and into the Company, with the Company as the surviving entity and a wholly owned subsidiary of Parent.
F4: Pursuant to the terms of the Merger Agreement, as of the Effective Time (i) a portion of the Company's common stock, par value $0.01 per share ("Company Common Stock") owned by the reporting person was converted into shares of Parent common stock, par value $0.01 per share, (ii)the remaining shares of Company Common Stock owned by the reporting person were converted into the right to receive $29.25 in cash without interest (the "Merger Consideration") and (iii) each outstanding restricted stock unit granted by the Company was converted automatically into a right to receive an amount in cash without interest equal to the product of (x) the number of shares of Company Common Stock subject to such unit, such number of shares based on target performance in the case of performance stock units, multiplied by (y) the Merger Consideration.
F5: The options vested in the following amounts on the following dates: 45,700 options on 03/25/2012, 45,700 options on 03/25/2013, 45,700 options on 03/25/2014 and 45,701 options on 03/25/2015.
F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding employee option, whether vested or unvested ("Company Stock Option") became fully vested and was converted automatically into the right to receive an amount in cash without interest equal to the product of (x) the number of shares of Company Common Stock subject to such option, multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price per share of such Company Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 07, 2017 Filed Dec 11, 2017 14:17 UTC | PharMerica CORP PMC · Entity 171237 | Disposition to issuerEmployee Stock Option · Derivative | 182,801 | $18.41 Strike: $10.84 | $3,365,366.41 |
DisclosureSEC source: 0001209191-17-064964 · doc4.xml · derivative · entry 7 WEISHAR GREGORY S · CIK 0001194422 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.01 per share · 182,801 shares Expires 2018-03-25 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding employee option, whether vested or unvested ("Company Stock Option") became fully vested and was converted automatically into the right to receive an amount in cash without interest equal to the product of (x) the number of shares of Company Common Stock subject to such option, multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price per share of such Company Stock Option. F5 · derivative.exercise_date: The options vested in the following amounts on the following dates: 45,700 options on 03/25/2012, 45,700 options on 03/25/2013, 45,700 options on 03/25/2014 and 45,701 options on 03/25/2015. Read SEC document |
| December 07, 2017 Filed Dec 11, 2017 14:17 UTC | PharMerica CORP PMC · Entity 171237 | Disposition to issuerPerformance share units · Derivative | 146,521 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001209191-17-064964 · doc4.xml · derivative · entry 6 WEISHAR GREGORY S · CIK 0001194422 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.01 per share · 146,521 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, as of the Effective Time (i) a portion of the Company's common stock, par value $0.01 per share ("Company Common Stock") owned by the reporting person was converted into shares of Parent common stock, par value $0.01 per share, (ii)the remaining shares of Company Common Stock owned by the reporting person were converted into the right to receive $29.25 in cash without interest (the "Merger Consideration") and (iii) each outstanding restricted stock unit granted by the Company was converted automatically into a right to receive an amount in cash without interest equal to the product of (x) the number of shares of Company Common Stock subject to such unit, such number of shares based on target performance in the case of performance stock units, multiplied by (y) the Merger Consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, as of the Effective Time (i) a portion of the Company's common stock, par value $0.01 per share ("Company Common Stock") owned by the reporting person was converted into shares of Parent common stock, par value $0.01 per share, (ii)the remaining shares of Company Common Stock owned by the reporting person were converted into the right to receive $29.25 in cash without interest (the "Merger Consideration") and (iii) each outstanding restricted stock unit granted by the Company was converted automatically into a right to receive an amount in cash without interest equal to the product of (x) the number of shares of Company Common Stock subject to such unit, such number of shares based on target performance in the case of performance stock units, multiplied by (y) the Merger Consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, as of the Effective Time (i) a portion of the Company's common stock, par value $0.01 per share ("Company Common Stock") owned by the reporting person was converted into shares of Parent common stock, par value $0.01 per share, (ii)the remaining shares of Company Common Stock owned by the reporting person were converted into the right to receive $29.25 in cash without interest (the "Merger Consideration") and (iii) each outstanding restricted stock unit granted by the Company was converted automatically into a right to receive an amount in cash without interest equal to the product of (x) the number of shares of Company Common Stock subject to such unit, such number of shares based on target performance in the case of performance stock units, multiplied by (y) the Merger Consideration. Read SEC document |
| December 07, 2017 Filed Dec 11, 2017 14:17 UTC | PharMerica CORP PMC · Entity 171237 | GrantPerformance share units · Derivative | 146,521 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001209191-17-064964 · doc4.xml · derivative · entry 5 WEISHAR GREGORY S · CIK 0001194422 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,521 Underlying: Common Stock, par value $0.01 per share · 146,521 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, as of the Effective Time (i) a portion of the Company's common stock, par value $0.01 per share ("Company Common Stock") owned by the reporting person was converted into shares of Parent common stock, par value $0.01 per share, (ii)the remaining shares of Company Common Stock owned by the reporting person were converted into the right to receive $29.25 in cash without interest (the "Merger Consideration") and (iii) each outstanding restricted stock unit granted by the Company was converted automatically into a right to receive an amount in cash without interest equal to the product of (x) the number of shares of Company Common Stock subject to such unit, such number of shares based on target performance in the case of performance stock units, multiplied by (y) the Merger Consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, as of the Effective Time (i) a portion of the Company's common stock, par value $0.01 per share ("Company Common Stock") owned by the reporting person was converted into shares of Parent common stock, par value $0.01 per share, (ii)the remaining shares of Company Common Stock owned by the reporting person were converted into the right to receive $29.25 in cash without interest (the "Merger Consideration") and (iii) each outstanding restricted stock unit granted by the Company was converted automatically into a right to receive an amount in cash without interest equal to the product of (x) the number of shares of Company Common Stock subject to such unit, such number of shares based on target performance in the case of performance stock units, multiplied by (y) the Merger Consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, as of the Effective Time (i) a portion of the Company's common stock, par value $0.01 per share ("Company Common Stock") owned by the reporting person was converted into shares of Parent common stock, par value $0.01 per share, (ii)the remaining shares of Company Common Stock owned by the reporting person were converted into the right to receive $29.25 in cash without interest (the "Merger Consideration") and (iii) each outstanding restricted stock unit granted by the Company was converted automatically into a right to receive an amount in cash without interest equal to the product of (x) the number of shares of Company Common Stock subject to such unit, such number of shares based on target performance in the case of performance stock units, multiplied by (y) the Merger Consideration. Read SEC document |
| December 07, 2017 Filed Dec 11, 2017 14:17 UTC | PharMerica CORP PMC · Entity 171237 | SaleCommon Stock, $0.01 par value | 1,500 | $29.25 | $43,875.00 |
DisclosureSEC source: 0001209191-17-064964 · doc4.xml · nonDerivative · entry 4 WEISHAR GREGORY S · CIK 0001194422 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Son Disclosed balance after: 0 F3 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of August 1, 2017 (the "Merger Agreement"), by and among PharMerica Corporation (the "Company"), Phoenix Parent Holdings Inc., a Delaware corporation ("Parent"), and Phoenix Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent, at the effective time ("Effective Time") of the merger, Merger Sub will merge with and into the Company, with the Company as the surviving entity and a wholly owned subsidiary of Parent. F4 · price: Pursuant to the terms of the Merger Agreement, as of the Effective Time (i) a portion of the Company's common stock, par value $0.01 per share ("Company Common Stock") owned by the reporting person was converted into shares of Parent common stock, par value $0.01 per share, (ii)the remaining shares of Company Common Stock owned by the reporting person were converted into the right to receive $29.25 in cash without interest (the "Merger Consideration") and (iii) each outstanding restricted stock unit granted by the Company was converted automatically into a right to receive an amount in cash without interest equal to the product of (x) the number of shares of Company Common Stock subject to such unit, such number of shares based on target performance in the case of performance stock units, multiplied by (y) the Merger Consideration. Read SEC document |
| December 07, 2017 Filed Dec 11, 2017 14:17 UTC | PharMerica CORP PMC · Entity 171237 | SaleCommon Stock, $0.01 par value | 519,589 | $29.25 | $15,197,978.25 |
DisclosureSEC source: 0001209191-17-064964 · doc4.xml · nonDerivative · entry 3 WEISHAR GREGORY S · CIK 0001194422 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 F3 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of August 1, 2017 (the "Merger Agreement"), by and among PharMerica Corporation (the "Company"), Phoenix Parent Holdings Inc., a Delaware corporation ("Parent"), and Phoenix Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent, at the effective time ("Effective Time") of the merger, Merger Sub will merge with and into the Company, with the Company as the surviving entity and a wholly owned subsidiary of Parent. F4 · price: Pursuant to the terms of the Merger Agreement, as of the Effective Time (i) a portion of the Company's common stock, par value $0.01 per share ("Company Common Stock") owned by the reporting person was converted into shares of Parent common stock, par value $0.01 per share, (ii)the remaining shares of Company Common Stock owned by the reporting person were converted into the right to receive $29.25 in cash without interest (the "Merger Consideration") and (iii) each outstanding restricted stock unit granted by the Company was converted automatically into a right to receive an amount in cash without interest equal to the product of (x) the number of shares of Company Common Stock subject to such unit, such number of shares based on target performance in the case of performance stock units, multiplied by (y) the Merger Consideration. Read SEC document |
| December 07, 2017 Filed Dec 11, 2017 14:17 UTC | PharMerica CORP PMC · Entity 171237 | Disposition to issuerCommon Stock, $0.01 par value | 440,001 | $29.25 | $12,870,029.25 |
DisclosureSEC source: 0001209191-17-064964 · doc4.xml · nonDerivative · entry 2 WEISHAR GREGORY S · CIK 0001194422 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of August 1, 2017 (the "Merger Agreement"), by and among PharMerica Corporation (the "Company"), Phoenix Parent Holdings Inc., a Delaware corporation ("Parent"), and Phoenix Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent, at the effective time ("Effective Time") of the merger, Merger Sub will merge with and into the Company, with the Company as the surviving entity and a wholly owned subsidiary of Parent. F4 · price: Pursuant to the terms of the Merger Agreement, as of the Effective Time (i) a portion of the Company's common stock, par value $0.01 per share ("Company Common Stock") owned by the reporting person was converted into shares of Parent common stock, par value $0.01 per share, (ii)the remaining shares of Company Common Stock owned by the reporting person were converted into the right to receive $29.25 in cash without interest (the "Merger Consideration") and (iii) each outstanding restricted stock unit granted by the Company was converted automatically into a right to receive an amount in cash without interest equal to the product of (x) the number of shares of Company Common Stock subject to such unit, such number of shares based on target performance in the case of performance stock units, multiplied by (y) the Merger Consideration. Read SEC document |
| November 03, 2017 Filed Dec 11, 2017 14:17 UTC | PharMerica CORP PMC · Entity 171237 | GiftCommon Stock, $0.01 par value | 51,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-064964 · doc4.xml · nonDerivative · entry 1 WEISHAR GREGORY S · CIK 0001194422 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,001 F1 · shares: On November 3, 2017, the reporting person irrevocably transferred 51,282 shares to the Weishar Family Foundation. F2 · balance_after: The reported securities do not include 519,589 shares transferred on November 3, 2017 to the Greg S. Weishar Delaware Trust, for which securities the reporting person disclaims beneficial ownership except to the extent of his pecuniary interest therein. Read SEC document |
| March 24, 2017 Filed Mar 28, 2017 17:13 UTC | PharMerica CORP PMC · Entity 171237 | Tax withholdingCommon Stock, $0.01 par value | 12,054 | $23.60 | $284,474.40 |
DisclosureSEC source: 0001209191-17-023161 · doc4.xml · nonDerivative · entry 2 WEISHAR GREGORY S · CIK 0001194422 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 960,792 Read SEC document |
| March 24, 2017 Filed Mar 28, 2017 17:13 UTC | PharMerica CORP PMC · Entity 171237 | GrantCommon Stock, $0.01 par value | 24,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-023161 · doc4.xml · nonDerivative · entry 1 WEISHAR GREGORY S · CIK 0001194422 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 972,846 Read SEC document |
| March 24, 2017 Filed Apr 11, 2017 17:02 UTC | PharMerica CORP PMC · Entity 171237 | GrantCommon Stock, $0.01 par value | 50,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-026587 · doc4.xml · nonDerivative · entry 1 WEISHAR GREGORY S · CIK 0001194422 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,010,872 Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 17:17 UTC | PharMerica CORP PMC · Entity 171237 | Tax withholdingCommon Stock, $0.01 par value | 6,433 | $23.15 | $148,923.95 |
DisclosureSEC source: 0001209191-17-022083 · doc4.xml · nonDerivative · entry 2 WEISHAR GREGORY S · CIK 0001194422 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 948,737 Read SEC document |
| March 17, 2017 Filed Mar 21, 2017 17:17 UTC | PharMerica CORP PMC · Entity 171237 | Tax withholdingCommon Stock, $0.01 par value | 9,640 | $22.50 | $216,900.00 |
DisclosureSEC source: 0001209191-17-022083 · doc4.xml · nonDerivative · entry 1 WEISHAR GREGORY S · CIK 0001194422 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 955,170 Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 16:30 UTC | PharMerica CORP PMC · Entity 171237 | Exercise / conversionStock Option (right to buy) · Derivative | 155,836 | $0.00 Strike: $18.48 | $0.00 |
DisclosureSEC source: 0001209191-17-021403 · doc4.xml · derivative · entry 3 WEISHAR GREGORY S · CIK 0001194422 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock ($.01 par value ) · 155,836 shares Expires 2017-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options vested in the following amounts on the following dates: 38,959 options on 03/16/2011, 38,959 options on 03/16/2012, 38,959 options on 03/16/2013 and 38,959 options on 03/16/2014. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 16:30 UTC | PharMerica CORP PMC · Entity 171237 | Exercise / conversionCommon Stock, $0.01 par value | 155,836 | $18.48 | $2,879,849.28 |
DisclosureSEC source: 0001209191-17-021403 · doc4.xml · nonDerivative · entry 1 WEISHAR GREGORY S · CIK 0001194422 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 964,810 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2017 Filed Mar 15, 2017 16:15 UTC | PharMerica CORP PMC · Entity 171237 | Tax withholdingCommon Stock, $0.01 par value | 5,987 | $23.00 | $137,701.00 |
DisclosureSEC source: 0001209191-17-020783 · doc4.xml · nonDerivative · entry 1 WEISHAR GREGORY S · CIK 0001194422 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 808,974 Read SEC document |
| April 03, 2006 Filed Apr 5, 2006 20:23 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantStock Option · Derivative | 46,106 | $0.00 Strike: $30.04 | $0.00 |
DisclosureSEC source: 0001194405-06-000015 · doc.xml · derivative · entry 2 WEISHAR GREGORY S · CIK 0001194422 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,106 Underlying: Common Stock · 46,106 shares Expires 2013-04-03 F1 · derivative.exercise_date: Option becomes exercisable in three equal annual installments, commencing 4/3/07 Read SEC document |
| April 03, 2006 Filed Apr 5, 2006 20:23 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantCommon Stock (Restricted) | 4,161 | $0.00 | $0.00 |
DisclosureSEC source: 0001194405-06-000015 · doc.xml · nonDerivative · entry 1 WEISHAR GREGORY S · CIK 0001194422 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,161 Read SEC document |
| August 10, 2005 Filed Aug 11, 2005 18:29 UTC | CVS HEALTH Corp CVS · Entity 2884 | SaleCommon Stock | 153,048 | $30.17 | $4,617,641.82 |
DisclosureSEC source: 0001194422-05-000001 · doc.xml · nonDerivative · entry 6 WEISHAR GREGORY S · CIK 0001194422 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,010 Read SEC document |
| August 09, 2005 Filed Aug 11, 2005 18:29 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionStock Option · Derivative | 26,624 | $0.00 Strike: $17.67 | $0.00 |
DisclosureSEC source: 0001194422-05-000001 · doc.xml · derivative · entry 12 WEISHAR GREGORY S · CIK 0001194422 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,376 Underlying: Common Stock · 26,624 shares Expires 2011-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Cash exercise funded by Insider. Read SEC document |
| August 09, 2005 Filed Aug 11, 2005 18:29 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionStock Option · Derivative | 9,010 | $0.00 Strike: $14.96 | $0.00 |
DisclosureSEC source: 0001194422-05-000001 · doc.xml · derivative · entry 11 WEISHAR GREGORY S · CIK 0001194422 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 9,010 shares Expires 2012-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Cash exercise funded by Insider. Read SEC document |
| August 09, 2005 Filed Aug 11, 2005 18:29 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionStock Option · Derivative | 60,000 | $0.00 Strike: $14.96 | $0.00 |
DisclosureSEC source: 0001194422-05-000001 · doc.xml · derivative · entry 10 WEISHAR GREGORY S · CIK 0001194422 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,010 Underlying: Common Stock · 60,000 shares Expires 2012-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Cash exercise funded by Insider. Read SEC document |
| August 09, 2005 Filed Aug 11, 2005 18:29 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionStock Option · Derivative | 40,000 | $0.00 Strike: $12.56 | $0.00 |
DisclosureSEC source: 0001194422-05-000001 · doc.xml · derivative · entry 9 WEISHAR GREGORY S · CIK 0001194422 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2013-01-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Cash exercise funded by Insider. Read SEC document |
| August 09, 2005 Filed Aug 11, 2005 18:29 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionStock Option · Derivative | 17,414 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001194422-05-000001 · doc.xml · derivative · entry 8 WEISHAR GREGORY S · CIK 0001194422 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,414 shares Expires 2007-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Cash exercise funded by Insider. Read SEC document |
| August 09, 2005 Filed Aug 11, 2005 18:29 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionCommon Stock | 26,624 | $17.67 | $470,379.52 |
DisclosureSEC source: 0001194422-05-000001 · doc.xml · nonDerivative · entry 5 WEISHAR GREGORY S · CIK 0001194422 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,058 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2005 Filed Aug 11, 2005 18:29 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionCommon Stock | 60,000 | $14.96 | $897,750.00 |
DisclosureSEC source: 0001194422-05-000001 · doc.xml · nonDerivative · entry 4 WEISHAR GREGORY S · CIK 0001194422 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2005 Filed Aug 11, 2005 18:29 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionCommon Stock | 9,010 | $14.96 | $134,812.13 |
DisclosureSEC source: 0001194422-05-000001 · doc.xml · nonDerivative · entry 3 WEISHAR GREGORY S · CIK 0001194422 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2005 Filed Aug 11, 2005 18:29 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionCommon Stock | 40,000 | $12.56 | $502,500.00 |
DisclosureSEC source: 0001194422-05-000001 · doc.xml · nonDerivative · entry 2 WEISHAR GREGORY S · CIK 0001194422 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2005 Filed Aug 11, 2005 18:29 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionCommon Stock | 17,414 | $11.50 | $200,261.00 |
DisclosureSEC source: 0001194422-05-000001 · doc.xml · nonDerivative · entry 1 WEISHAR GREGORY S · CIK 0001194422 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2005 Filed Jan 7, 2005 21:22 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantStock Option · Derivative | 30,000 | $0.00 Strike: $44.89 | $0.00 |
DisclosureSEC source: 0001194405-05-000008 · c0001194422d20050107f4f.xml · derivative · entry 2 WEISHAR GREGORY S · CIK 0001194422 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2012-01-05 F1 · derivative.exercise_date: Option becomes exercisable in three equal annual installments, commencing 01/05/2006. Read SEC document |
| January 05, 2005 Filed Jan 7, 2005 21:22 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantCommon Stock (Restricted) | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001194405-05-000008 · c0001194422d20050107f4f.xml · nonDerivative · entry 1 WEISHAR GREGORY S · CIK 0001194422 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Read SEC document |
| January 08, 2004 Filed Jan 12, 2004 20:13 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantStock Option · Derivative | 40,000 | $0.00 Strike: $35.34 | $0.00 |
DisclosureSEC source: 0001194416-04-000007 · c0001194422d20040112f4f.xml · derivative · entry 5 WEISHAR GREGORY S · CIK 0001194422 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2011-01-08 F1 · derivative.exercise_date: Options become exercisable in three equal annual installments, commencing 01/08/2005. Read SEC document |
| January 08, 2004 Filed Jan 12, 2004 20:13 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantCommon Stock (Restricted) | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001194416-04-000007 · c0001194422d20040112f4f.xml · nonDerivative · entry 1 WEISHAR GREGORY S · CIK 0001194422 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Read SEC document |
| December 31, 2003 Filed Feb 10, 2004 16:06 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantPhantom Stock Credits · Derivative | 4,972 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001194405-04-000007 · c0001194422d20040210f5f.xml · derivative · entry 4 WEISHAR GREGORY S · CIK 0001194422 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,972 Underlying: Common Stock · 4,972 shares Expires not disclosed F3 · derivative.exercise_price: Each share credit is equivalent to one share; 1-for-1 conversion. F4 · shares: Reflects 2001, 2002 and 2003 year end company match share credits of 323, 575 and 730, respectively, and 2002 and 2003 employee contribution share credits of 783 and 2,561, respectively, under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person. F4 · derivative.exercise_date: Reflects 2001, 2002 and 2003 year end company match share credits of 323, 575 and 730, respectively, and 2002 and 2003 employee contribution share credits of 783 and 2,561, respectively, under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person. F4 · derivative.expiration_date: Reflects 2001, 2002 and 2003 year end company match share credits of 323, 575 and 730, respectively, and 2002 and 2003 employee contribution share credits of 783 and 2,561, respectively, under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.